Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tesaro's Varubi Wins FDA Approval; Shares Up

This article was originally published in Scrip

Executive Summary

Shares of Tesaro jumped about 10% on Sept. 2 on the news the FDA had approved the Waltham, MA firm's new drug application to market Varubi (rolapitant) to prevent delayed phase chemotherapy-induced nausea and vomiting (CINV) in adults.

Advertisement

Related Content

US FDA’s First Complete Response Letter Of 2017 Involves … Manufacturing

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

SC029668

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel